Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|>99% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|>99% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|>99% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|>99% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
HomeNewsScience
Science

AAPS PharmSci 360 2026: Key Peptide Synthesis Conference Presentation Insights

The upcoming AAPS PharmSci 360 conference, scheduled for October 25-28, 2026, is expected to feature significant presentations on peptide drug delivery, solid-phase peptide synthesis (SPPS) advances, and formulation stability. This report summarizes key anticipated topics and their relevance for peptide researchers and industry professionals.

VP

Volta Peptides

Editorial Team

July 26, 2026Updated July 26, 20263 min read

Key Takeaways

  • The American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 conference, scheduled for October 25 to 28, 2026, is expected to feature a range of presentations focused on peptide therapeutics.
  • One of the primary areas of focus at the upcoming AAPS PharmSci 360 is expected to be solid-phase peptide synthesis (SPPS).
  • Another anticipated highlight of the conference is the focus on peptide formulation and stability.

The American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 conference, scheduled for October 25 to 28, 2026, is expected to feature a range of presentations focused on peptide therapeutics. According to early reports, the meeting will cover advances in peptide drug delivery, formulation stability, solid-phase peptide synthesis (SPPS), and CDMO capabilities. For researchers and industry professionals tracking the latest in peptide synthesis, this conference represents a key opportunity to learn about emerging trends and technologies.

Peptide Synthesis Advances at AAPS PharmSci 360

One of the primary areas of focus at the upcoming AAPS PharmSci 360 is expected to be solid-phase peptide synthesis (SPPS). According to sources, several presentations will highlight recent improvements in SPPS efficiency, including new resin chemistries and coupling reagents that can enhance yield and purity. These advances are particularly relevant for researchers working on complex peptide sequences that require careful optimization. For those interested in practical tools for peptide research, Volta Peptides offers a Peptide Reconstitution Calculator-calculator) and a Peptide Dosage & Cycle Planner-cycle-planner) to support experimental design.

Peptide Formulation and Stability Presentations

Another anticipated highlight of the conference is the focus on peptide formulation and stability. Early reports suggest that sessions will address challenges such as aggregation, degradation, and bioavailability of peptide drugs. Researchers may present data on novel excipients and formulation strategies that improve the shelf life and in vivo performance of peptide therapeutics. These discussions are critical for translating promising peptide candidates from the lab to clinical applications. For more information on peptide stability, researchers can consult the Stability Calculator on the Volta Peptides website.

The conference is also expected to feature presentations from contract development and manufacturing organizations (CDMOs) on their capabilities in peptide synthesis and formulation. According to partial information, these sessions will cover scale-up strategies, quality control methods, and regulatory considerations for peptide-based drugs. This is particularly relevant for companies looking to outsource production or accelerate their development timelines. The Volta Peptides Peptide Glossary provides definitions of key terms used in these discussions.

Significance for Peptide Researchers and Biohackers

For peptide researchers and biohackers, the AAPS PharmSci 360 conference offers a chance to stay informed about the latest scientific developments. While the conference is primarily industry-focused, the topics covered have direct implications for research compound quality and experimental design. Advances in SPPS and formulation stability can influence the purity and consistency of peptides used in research. For those who cannot attend, following post-conference summaries and accessing tools like the Purity Analyzer can help apply these insights to their own work.

FAQ

Q: When is the AAPS PharmSci 360 conference scheduled?

A: The conference is reportedly scheduled for October 25 to 28, 2026. These dates are based on partial information and may be subject to change.

Q: What topics will be covered at the peptide synthesis conference presentation?

A: According to early reports, the conference will cover solid-phase peptide synthesis (SPPS) advances, peptide formulation and stability, and CDMO capabilities for peptide drug development.

Q: How can researchers benefit from attending or following this conference?

A: Researchers can learn about the latest techniques in peptide synthesis and formulation, which can improve the quality and reproducibility of their experiments. Tools like the Peptide Half-Life Calculator-calculator) can help apply these insights to practical research scenarios.

Research Use Only. This article is provided for informational and educational purposes only. The compounds and topics discussed are intended solely for laboratory and scientific research. This content does not constitute medical advice, and Volta Peptides does not endorse or promote human consumption of any research compound.

More from Volta Peptides

Science

US Peptide Synthesis Reagents Market Analysis and Forecast

IndexBox has released a comprehensive market analysis for peptide synthesis reagents in the United States, covering size, trends, and forecasts. The report provides detailed insights into the industry's current state and future outlook. Key data points include market volume, value, and growth projections.

Aug 10· min read
Science

Weight-Loss Pill's Unexpected Effect Stuns Researchers

A new weight-loss pill produced an outcome that researchers did not anticipate. The finding, reported by Earth.com, challenges assumptions about how such medications work. Details of the study remain limited, but the unexpected result has drawn attention in the scientific community.

Aug 2· min read
Science

Generative AI Optimizes Peptide Antibiotics in Nature

A study published in Nature on May 13, 2026, details a generative artificial intelligence approach for peptide antibiotic optimization. The paper focuses on this AI method applied to peptide antibiotics. Researchers present the approach in the journal Nature.

May 13· min read
Science

Ascidian and Lilly Sign $1.9B RNA Editing Kidney Pact

Ascidian Therapeutics and Eli Lilly have signed a research collaboration potentially worth up to $1.9 billion. The agreement gives Eli Lilly the opportunity to discover and develop RNA exon editing therapeutics aimed at genetic kidney diseases. The deal focuses on advancing these treatments through joint research efforts.

Jun 3· min read
General

Semaglutide News: A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide

A recent case report has highlighted a potential risk factor for patients taking tirzepatide: severe hypercalcemia. This semaglutide news analysis explores the reported incident, possible mechanisms, and implications for peptide researchers and clinicians, emphasizing the need for careful monitoring of electrolyte imbalances in GLP-1 receptor agonist therapies.

Jul 26· min read
Regulatory

Roche Secures CE Mark for Second Eli Lilly Alzheimer’s Test

Roche has obtained a European CE mark for its second Alzheimer’s test developed with Eli Lilly. The diagnostic can confirm the disease or rule it out. This approval enables use across Europe for better patient assessment.

May 13· min read

Your Cart

Your cart is empty

Browse our catalog to add research compounds.